Curative vs. Palliative Treatment Considerations in Y90 Dosing

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
How does Y90 dosimetry change depending treatment intent and HCC tumor location? Dr. Kirema Garcia-Reyes describes her strategy of selective embolization for multifocal lesions.

Featuring our panel of interventional radiologists:
- Dr. Tyler Sandow
- Dr. Sabeen Dhand
- Dr. Zach Berman
- Dr. Sid Padia
- Dr. Kirema Garcia-Reyes


Stream the full episode here: https://youtu.be/mtknCLeDAXY

Enroll in our free BackTable+ course on Y90 Dosimetry for CME credits: https://plus.backtable.com/courses/Y-90-Dosing-and-Ablation-Modalities-for-Hepatocellular-Carcinoma

This content was made possible through funding from AstraZeneca and Boston Scientific educational grants.

#ONC2 #HCC #HepatocellularCarcinoma #Cancer #Oncology #Immunotherapy #DrugDevelopment #Pharmaceuticals #InterventionalRadiology #Multidisciplinary #CancerCare #Oncologist #LiverCancer #Medical #Innovation #Physician #Surgeon #TransplantSurgery #Hepatobiliary #Y90 #TARE #Locoregional #Dosimetry #NuclearMedicine
Category
Oncology
Be the first to comment

Up Next